AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01623232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAS-1 adjuvant and influenza HA antigen
Description: Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.~1. Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).~2. Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.~3. Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.
Study NCT01623232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: standard dose, inactivated trivalent influenza vaccine (TIV)
Description: Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.~4. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains.
Study NCT02731833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stannous fluoride
Description: 0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride
Study NCT02731833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium monofluorophosphate
Description: 0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
Study NCT01880645 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine Needle Aspiration (FNA)
Description: If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
Study NCT01880645 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
Study NCT01880645 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast Surgery + Lymph Node Removal
Description: Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
Study NCT00852956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betahistine
Description: The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00
Study NCT00852956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine
Description: The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00
Study NCT00686790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PegIntron, SCH 54031)
Description: Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
Study NCT03774927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz treatment group
Description: 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
Study NCT03774927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz treatment group
Description: 20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
Study NCT03774927 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
Study NCT01450579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7373
Description: Intermuscular administration
Study NCT01450579 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study NCT03644602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAPs diet
Description: Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)
Study NCT04323436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spartalizumab placebo
Description: dextrose 5% in water (D5W) for infusion
Study NCT02848417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
Study NCT02848417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
Study NCT02848417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions.
Study NCT00760864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-715 and methotrexate
Description: TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Study NCT00760864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-715 and methotrexate
Description: TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Study NCT00760864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-715 and methotrexate
Description: TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Study NCT00760864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
Study NCT02399579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provocation test
Description: The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
Study NCT01178853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin 5 mg once daily
Study NCT01178853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
Description: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
Study NCT01178853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
Description: Warfarin 5 mg + Pitavastatin 4mg
Study NCT04110808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypotensive anaesthesia using Nitroglycerine
Description: effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.
Study NCT04110808 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: hypotensive anaesthesia using Nitroglycerine
Description: effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.
Study NCT03999619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 2 Learn
Description: 10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
Study NCT03999619 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Move 2 Learn
Description: 10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
Study NCT01316367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRECEDE HPE model
Description: The model considers the influence of the following three factors on health-related behavior:~* Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~* Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~* Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it.
Study NCT01316367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHPE
Description: The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
Study NCT03563495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tissue engineered group
Description: cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)
Study NCT03563495 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autogenous bone graft group
Study NCT03815851 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: prophylactic drainage
Description: place prophylactic drainage after surgery
Study NCT03815851 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: no prophylactic drainage
Description: Not place prophylactic drainage after surgery
Study NCT04343989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
Study NCT02539602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Need to Know students received the N2K curriculum as described previously
Study NCT01396122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System
Description: Perform surgery with GYNECARE PROSIMA\* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
Study NCT02161393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
Study NCT02161393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation Programme
Description: This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
Study NCT02873442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
Study NCT02873442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
Study NCT02873442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cells
Description: DC cell suspension (1×107 DC+ physiological saline~+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT02956915 — intervention group
Intervention type: PROCEDURE
Intervention: Transfemoral Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
Study NCT02409732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid hydrochloride
Study NCT02621827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral dose of stable isotope labeled 25(OH)D3
Description: At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
Study NCT02409732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with blue light
Study NCT00306735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Study NCT03320941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally daily.
Study NCT03320941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as tablets to be taken daily orally.
Study NCT01090076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
Description: Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
Study NCT01090076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
Description: Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
Study NCT02674971 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common components of intervention
Description: 12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
Study NCT03877133 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Near-infrared spectroscopy
Description: Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
Study NCT02321371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose + Rifaximin
Description: Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
Study NCT02321371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Continuation of Lactulose therapy for further 48 hours.
Study NCT00553800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00553800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT00513565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose
Description: Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
Study NCT01877720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive respiratory support with NAVA mode and PSV
Study NCT02920216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
Study NCT00513565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single dose
Description: Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
Study NCT00357747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEG35156
Description: After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
Study NCT00357747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
Study NCT00513565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: single dose
Description: Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.